Trial Profile
Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Cyclophosphamide
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 11 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 11 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 01 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.